MorphoSys slides on bimagrumab miss

MorphoSys AG (Xetra:MOR) fell EUR 8.62 (17%) to EUR 41.78 on Thursday after bimagrumab ( BYM338) missed the primary endpoint in a Phase II/III trial to treat sporadic inclusion body myositis (sIBM). MorphoSys' partner Novartis AG (NYSE:NVS; SIX:NOVN) conducted the trial. ClinicalTrials.gov lists the primary endpoint as change in six-minute walk distance (6MWD) from baseline to week 52.

Neither partner reported detailed data. Novartis said it is reviewing the data to inform decisions on development of the human HuCAL antibody against activin receptor type 2B ( ACVR2B). ...